 Arbutus Biopharma Corp NASDAQ: ABUS shares are trading higher after the company announced it received a 40M upfront payment from Qilu to commercialize AB-729 in Asia. William Collier, President and Chief Executive Officer of Arbutus Biopharma, commented, Qilu is an ideal partner for our AB-729 RNAi therapeutic given their extensive development, regulatory and commercialization capabilities in China. 